Status:
UNKNOWN
Acute Haemodynamic Effects of Treatment With Angiotensin Converting Enzyme (ACE)-Inhibitors in Patients With Symptomatic Aortic Stenosis
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Aortic Stenosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Abundant evidence suggests that Angiotensin Converting Enzyme (ACE) inhibition potentially could reduce the hazardous effects of aortic stenosis and improve haemodynamics. The treatment seems safe eve...
Detailed Description
Traditionally vasodilators are contraindicated in patients with aortic stenosis. Although no controlled data exists it is believed to be hazardous to reduce afterload, including treatment with angiote...
Eligibility Criteria
Inclusion
- Valvular aortic stenosis with a aortic valve area \< 1, 0 cm2
- Age \> 18 years
- Willingness to give written informed consent
- For patients with symptomatic aortic stenosis at least one of following:
- Stable angina pectoris
- Syncope at exertion
- Dizziness at exertion
- Previous pulmonary oedema
- Patients in New York Heart Association functional class II-IV
Exclusion
- Sitting systolic pressure \< 100 mmHg
- Creatinine \> 200 mM at screening
- Renal artery stenosis
- Pregnancy or planned pregnancy
- Participation in other studies
- Any patient characteristic that may interfere with compliance with the study protocol
- Treated with ACE-inhibitor or angiotensin receptor blocker within the last month
- Known allergy to ACE-inhibitors
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2008
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00252317
Start Date
November 1 2005
End Date
October 1 2008
Last Update
September 3 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet, Copenhagen University Hospital
Copenhagen, KBH Ø, Denmark, 2100